May 16, 2022 5:34pm
A scorecard of earnings releases of covered companies - 31 of 35 - so far
The current LPS (loss per share) or net income, cash positions i.e. "runways" is a reflection of this universe's investing "status".
5/16 adding Brainstorm Cell Therapeutics (BCLI), Homology Medicine FIXX) and Biostage (BSTG)
|
COMPANY |
SYMBOL | NET INCOME |
Q1/22 LOSS |
Q1/22 LPS |
CASH POSITION | RUNWAY |
|---|---|---|---|---|---|---|
|
Chinook Therapeutics
|
KDNY 5/12 |
-$31.7 M |
-$0.54 |
$330 M | 2025 | |
|
Agenus
|
AGEN
|
-$51M |
-$0.19 |
$263 M | 2025 | |
|
Alnylam Pharmaceuticals |
ALNY Q1/22 |
-$234.34 M
|
Q1/22 - $2.00
|
$2.24 B
|
NA
|
|
| Applied Genetic Technologies |
AGTC
|
|
|
|
||
|
Athersys |
ATHX
|
|
|
2022 | ||
|
Adverum Biotechnologies |
ADVM 5/12 |
-$37.9 M |
-$0.38 |
$271.1 M | 2024 | |
|
AVROBIO
|
AVRO
|
-$29.8 M |
-$0.68 |
$161.7 M | Q1/2024 | |
|
AxoGen |
AXGN Q1/22 |
-$8.5 M |
-$0.20 |
$73.7M |
2024 |
|
|
Bellicum Pharmaceuticals |
BLCM 5/12 |
|
-$7.6 M |
-$0.25 | $41.3 M | 2023 |
|
Beam Therapeutics |
BEAM |
-$69.2 M |
-$1.01 |
$1.2 B | 2025 | |
|
BioLife Solutions |
BLFS 5/9 |
|
-$7.1 M |
-$0.17 |
$59.5 M |
2025 |
| Biostage |
BSTG |
-$2.2 M |
-$0.20 |
$700 K Legal liabilitiesof $1.5 M and yet another (6th) Private Placement Debt |
Q4/22 | |
|
bluebird bio
|
BLUE 5/9 |
-$122.2 M |
-$1.66 |
$312 M |
Q1/2023 |
|
|
Brainstorm Cell Therapeutics
|
BCLI |
-$5.36 M |
-$015 |
$18.4 M | 2022 | |
|
Caribou Biosciences |
CRBU |
|
|
|||
| Cellectis SA |
CLLS 5/12 |
|
-$32 M |
-$0.70 |
$142 M |
2025 |
|
CRISPR Therapeutics |
CRSP 5/9 |
|
-$179.2 M |
-$2.32 |
$2,221.3 M | 1H/2025 |
|
Editas Medicine |
EDIT Q1/22 |
|
-$50.15 M
|
-$0.74
|
$566.4 M
|
Q1/2024
|
|
Fate Therapeutics |
FATE Q1/22 |
-$65.9 M
|
-$0.68 |
$641.7 M |
2024 |
|
|
Global Blood Therapeutics |
GBT Q1/22 |
-$81.4 M |
-$1.26
|
$662.1M |
Q1/25 | |
|
Homology Medicine |
FIXX |
+$92.1 M or +$1.59 per share |
|
$256.1 M | 2H/2024 | |
|
Intellia Therapeutics |
NTLA
|
-$146.9 M |
-$1.96 |
$994.7 M (-$38.9 M ATM and -$8.4 ESOP drawdown |
2024 | |
|
Precigen |
PGEN 5/9
|
-$19.3 M |
-$0.10 |
$142.1 M | 2024 | |
|
Ionis Pharmaceuticals |
IONS Q1/22 |
|
Q1/22 -$65 M
|
Q1/22 -$0.46
|
$2.1 B
|
N/A
|
| Mesoblast |
MESO
|
|
2023 | |||
| MiMedx Group |
MDXG Q1/22 |
|
-$10.5 M
|
-$0.11
|
$75.7 M
|
2024
|
|
Pluristem Therapeutics |
PSTI | |||||
|
Regenxbio
|
RGNX Q1/22 |
|
-$76.7 M |
-$1.79 |
$764.8 M | 2025 |
|
Sage Therapeutics |
SAGE Q1/22 |
-122. M
|
-$2.07
|
$1.6 B
|
2025
|
|
|
Sangamo Biosciences |
SGMO Q1/22 |
-$44 M |
-$0.30 |
$400.3 M | 2023 | |
|
Solid Biosciences |
SLDB 3/13 |
|
|
Q3/2023 | ||
|
Ultragenyx Pharmaceuticals |
RARE |
-$152.3 M |
-$2.19 |
$813.8 M | 2024 | |
|
uniQure N.V.
|
QURE Q1/22 |
|
-$46.7 M |
-$1.00 |
$524.9 M | 1H/2025 |
|
Verastem Oncology |
VSTM 5/9 |
-$17 M |
-$0.09 |
$106.3 M (-$25 M drawdown from ATM) |
2024 | |
|
Vericel
|
VCEL Q1/22 |
|
-$7.1 M
|
-$0.015
|
$130 M
|
2024
|
|
Voyager Therapeutics |
VYGR Q1/22 |
|
-$21.3 M
|
-$0.56
|
$160.8 M
|
2024
|
